LEADER trial: difference between revisions
Diff·revision 5 → 6·08:46, 24 Oct 2024
Difference between revision 5 and revision 6 of LEADER trial. 3 lines changed; the page grew by 170 bytes.
| Revision 5 — 01:55, 10 Oct 2024 ParentCatPansy (talk) add the number randomised and the number completing 2,187 bytes +223 | Revision 6 — 08:46, 24 Oct 2024 PreregPriya (talk) add category for the trial programme 2,357 bytes +170 | ||
|---|---|---|---|
| 18 | The population was enriched for events: participants were 50 or older with established cardiovascular, cerebrovascular or renal disease, or 60 or older with risk factors. Enrichment increases the event rate and therefore the power of a trial of a given size, and it also limits generalisation to lower-risk populations.{{r|ich_e9}} | 18 | The population was enriched for events: participants were 50 or older with established cardiovascular, cerebrovascular or renal disease, or 60 or older with risk factors. Enrichment increases the event rate and therefore the power of a trial of a given size, and it also limits generalisation to lower-risk populations.{{r|ich_e9}} |
| 19 | 19 | ||
| + | 20 | Background therapy was standard care, so as in [[SELECT trial|SELECT]] the effect measured is incremental to contemporary treatment. | |
| + | 21 | ||
| 20 | == References == | 22 | == References == |
| 21 | {{reflist}} | 23 | {{reflist}} |
| ⋮ | ⋮ | ||
| 26 | [[Category:Cardiovascular outcome trials]] | 28 | [[Category:Cardiovascular outcome trials]] |
| 27 | [[Category:Clinical evidence]] | 29 | [[Category:Clinical evidence]] |
| + | 30 | [[Category:Type 2 diabetes trials]] | |
| 28 | 31 |